Survival Benefit of Statins in Hemodialysis XXXX Awaiting Renal Transplantation.

@entity1 @entity101 @entity6 @entity7774 @entity4346 @entity453 @entity6817 @entity454
@entity454 ( @entity454 ) @entity1 have extraordinarily high cardiovascular risk and mortality, yet the benefit of statins in this population remains unclear based on the randomized trials. We investigated the prognostic value of statins in a large, pure cohort of prospectively recruited @entity1 with @entity454 awaiting renal transplantation, and being followed up in a dedicated cardiac clinic. We prospectively collected demographic, clinical, laboratory, and pharmacological data on 423 consecutive @entity454 @entity1 on hemodialysis awaiting renal transplantation. Survival analysis was performed as a function of statin therapy. The baseline characteristics were as follows: age 57        11 years, males 64%, @entity6 in 68%, known @entity453 in 30%, left ventricular (LV) ejection fraction 61        11%. Over a mean follow-up of 2 years, there were 43 deaths. Adjusted for age, gender, @entity101 , body mass index, @entity6 , @entity453 , smoking, and treatment with @entity7774 converting enzyme inhibitor, b blocker, and antiplatelet medications, @entity6817 use was a predictor of lower mortality (hazard ratio 0.30, 95% confidence interval 0.11-0.79, p   =   0.01). This beneficial effect of statin was supported by propensity score analysis (p   =   0.02) and was consistent across all clinical subgroups. The benefit of statins seemed to be greater in those with @entity4346 and smoking. Statin therapy in hemodialysis @entity1 awaiting renal transplant is independently associated with better survival supporting its use in this high-risk population.
